Cellectar Biosciences Inc expected to post a loss of 48 cents a share - Earnings Preview

Cellectar Biosciences

11/08/2026 14:24

Cellectar Biosciences Inc CLRB.OQ CLRB.O is expected to  show no change in quarterly revenue when it reports  results on August 13 for the period ending June 30 2026

​LSEG's mean analyst estimate for Cellectar Biosciences Inc is for a loss of 48 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Cellectar Biosciences Inc is $10.00, about 284.6% above its last closing price of $2.60
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-1.63
-1.88
-1.30
Beat
31
Dec. 31 2026
-1.22
-2.29
-1.29
Beat
43.8
Sep. 30 2025
-2.56
-2.53
-1.41
Beat
44.2​
Jun. 30 2025
-3.60
-3.90
-3.39
Beat
13.1
​​Mar. 31 2025
-4.50
-4.90
-4.20
Beat
14.3
Dec. 31 2024
-10.07
-10.57
-1.80
Beat
83​
Sep. 30 2024
-12.90
-11.17
-12.00
Missed
-7.4
Jun. 30 2024
-9.42
-10.35
-0.90
Beat
91.3
This summary was machine generated August 11 at 13:24 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)